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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Acquired hemophilia A (AHA) is a rare disorder that has not been
comprehensively reported in the Chinese population. Treatment-related fatal sepsis (TRS),
other than hemorrhage, is the leading cause of death in patients with AHA. However, re-
searchers have not systematically evaluated salient parameters, to determine their association
with the risk of TRS in this rare disorder. This study reports the salient features of AHA in Chi-
nese patients and presents possible factors associated with TRS.
Methods: Sixty-five Chinese patients with AHA, including 42 men and 23 women, were studied
retrospectively.
Results: The median age was 64 years (range Z 18e94 years). The features, laboratory find-
ings, and outcomes of various therapies designed to arrest acute bleeding and eliminate auto-
antibodies against the factor VIII coagulant protein (VIIIi) were comparable to those previously
reported. The complete response (CR) rate was 60%, and the median time to CR was 16 weeks.
Ten patients (15%) died of bleeding related to FVIIIi by the end of the median follow-up period
of 115 months. The estimated 1- and 5-year hemorrhage-related mortality rates were 15% and
22%, respectively. The absence of CR to therapy was the only independent factor associated
with shorter survival. The rate of TRS was 20%, and the use of a rituximab-based (Rb) regimen
(odds ratio Z 8.0, 95% CI, 1.1e68.2) and platelet < 1.5  1011/L at diagnosis (odds
ratio Z 38.5, 95% CI, 1.3e1107.6) were the two significantly independent factors associated
with TRS.of Internal Medicine, Chang-Hua Christian Hospital, 135 Nanhsiao Street, Changhua 500, Taiwan.
(M.-C. Shen).
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322 S.-Y. Huang et al.Conclusion: The salient features of AHA and treatment outcomes of the patients in this study
are similar to those of other patients. Two independent factors (the use of a Rb regimen and
platelet < 1.5  1011/L) were significantly associated with TRS.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Acquired hemophilia A (AHA) is a rare disorder caused by
the spontaneous development of autoantibodies against
the FVIII coagulant protein (FVIIIi) in the nonhemophiliac
population. The incidence of AHA is approximately 1e4 per
million per year, and increases with age until 70e80 years.
There are no sex differences in AHA distribution at any age
except 20e40 years, when the preponderance of AHA in
women is pregnancy-related.1,2
Because FVIIIi-related hemorrhages are associated with
high morbidity and mortality, aggressive treatment of AHA
is recommended.3 The main goals of AHA therapy are to
arrest bleeding and eliminate FVIIIi. There are two main
options for controlling acute bleeding in patients with AHA;
the use of bypassing agents and raising FVIII levels.1e4 Re-
searchers have proposed the use of long-term conventional
immunosuppressive (IS) therapy, consisting of corticoste-
roids alone or combined with cytotoxic agents (CTAs), such
as cyclophosphamide, azathioprine, cyclosporine, or
tacrolimus, to eliminate FVIIIi.1,4,5 Several emerging
treatments [e.g., anti-CD20 antibody (rituximab),6e8 or
immune tolerance treatment (ITT)9,10] can efficiently
eliminate FVIIIi. However, no comparative studies have
been performed to evaluate the efficacy and safety of
these treatments, because the number of available pa-
tients is relatively small.1
Treatment-related fatal sepsis (TRS), in addition to
hemorrhage, is also a leading cause of death in patients
with AHA.2e4 A recent study, using a retrospective review of
death certificates, analyzed the deaths of 121 patients with
AHA and determined that hemorrhagic shock and infectious
events related to IS treatment were the most frequent
causes of death.11 Therefore, IS therapy should be strictly
tailored to patient characteristics (i.e., age, sex, and
general health status) to minimize adverse treatment-
related effects.2 Some prophylactic strategies may also
be required, particularly for infectious processes in AHA
patients during the treatment, to eradicate FVIIIi. To date,
no salient parameters have been systemically evaluated to
determine the risk of TRS in this rare disorder. Therefore,
this study retrospectively examines the clinical character-
istics and treatment outcomes of a relatively sizable cohort
of Chinese patients with AHA, and surveys any parameter
associated with TRS.
Patients and methods
Patients
This study retrospectively investigates 65 Chinese patients
with AHA in the hemophilia centers of two institutes,
between September 1987 and April 2010.Diagnosis and laboratory tests
The diagnosis of AHA required laboratory confirmation of
FVIIIi levels in patients with no preexisting coagulopathy.12
FVIIIi level was assayed using the Bethesda method,13 and
any plasma sample with an inhibitor level  0.6 Bethesda
units (BUs) was considered positive. All blood sampling and
laboratory procedures used in this study were described
previously.14
Treatment and response
To arrest acute bleeding, patients were treated with one or
more of the following agents: prothrombin complex
concentrate (PCC) [Konyne-80 (Miles-Cutter, Berkeley, CA,
USA), Proplex T, (Hyland Laboratories, Glendale, CA, USA)],
activated prothrombin complex concentrate (APCC) (FEIBA;
Baxter Immuno AG, Vienna, Austria), recombinant human
activated factor VII (rFVIIa) (NovoSeven; Novo Nordisk A/S,
Bagsvaerd, Denmark), hFVIII concentrate (Haemate P;
Behringwerke, Marburg, Germany), and pFVIII (Hyate:C;
Porton-Speywood, Ltd, Wrexham, UK). Plasma exchange
was performed to remove approximately 3000 mL of
plasma. Protein A sepharose columns were used for
immunoabsorption. The relevant doses and schedules were
similar to those described previously.2,12 Acute bleeding
was defined as new-onset bleeding requiring treatment.
Severe bleeding was defined as bleeding from visceral or-
gans, or the retroperitoneal compartment, or as life-
threatening bleeding. The selection of agents or therapies
depended on the patient’s condition and agent/therapy
availability. Control of acute bleeding was defined as he-
mostasis, no increase in hematoma size, and the absence of
any new bleeding signs.
Thirty of the patients received prednisolone alone as the
primary treatment, to eliminate FVIIIi for the first 6e8
weeks. Complete response (CR) was defined as a resolution
of hemorrhagic signs, complete disappearance of FVIIIi, and
the normalization of FVIII coagulant (FVIII:C). If the
response was less than complete, CTA was added. Initial
therapies included prednisolone and CTA simultaneously
(PCTA) in 14 patients, CTA alone in two patients, immune
tolerance therapy (ITT)9 in three patients, and rituximab-
based (Rb) regimens in seven patients (5 patients treated
with concomitant prednisolone and/or CTA and 2 patients
treated with rituximab alone). The doses and schedules of
prednisolone, CTA and rituximab, and the IT regimen, were
similar to those reported elsewhere.2,3,12
Statistical analysis
The Chi-square or Fisher’s exact test was used for between-
group comparisons of the discrete variables. A two-sample
Figure 1 The age distribution of 65 patients with acquired
hemophilia A.
Table 1 Clinical presentations of the 65 patients with
acquired hemophilia A.
Clinical presentation Patient, n (%)
Ecchymosis 53 (82)
Hematoma 42 (65)
Soft tissue 37 (57)
Retroperitoneal 5 (8)
Mucosal bleeding 28 (43)
Gastrointestinal tract 19 (29)
Urinary tract 8 (12)
Intracranial 1 (2)
Prolonged postoperative bleeding 14 (22)
Hemarthrosis 2 (3)
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means. The time to CR (TCR) was defined from the starting
date of FVIIIi elimination therapy, to the date at which CR
was documented. Bleeding specific mortality (BSM) was
defined as death caused by FVIIIi-related bleeding. Event-
free survival (EFS) was defined from the date of AHA diag-
nosis, to the date of BSM or the last follow-up. For EFS
estimates, the patients who died because of other causes
were considered alive and were lost to follow-up; thus, the
patient status at the last follow-up was regarded as a
censored event. Overall survival (OS) was calculated from
the date of AHA diagnosis to the date of death for any
reason, or to the last follow-up. This study uses Kaplan-
Meier survival curves to estimate TCR, BSM, EFS, and OS,
and compares the differences between groups using the log-
rank test. Several clinical and laboratory variables at diag-
nosis were assessed to determine their impact on survival.
These were sex, age, associated conditions, FVIII:C, titer of
FVIIIi, levels of hemoglobin (Hb), white blood cell count
(WBC), platelet count (PLA), albumin (Alb) level, lactate
dehydrogenase (LDH) level, and activated partial thrombo-
plastin time (APTT). As in previous reports,4 the continuous
variables were categorized on the basis of cut-off values as
follows: age> 65 years, FVIII:C< 1%, low-titer FVIIIi< 5 BU,
intermediate-titer FVIIIi 5e10 BU, high-titer FVIIIi > 10
BU  50 BU, very high-titer FVIIIi > 50 BU, Hb < 8 g/dL,
WBC < 4.0  109/L, PLA < 1.5  1011/L, Alb < 3.5 g/dL,
LDH > 465 IU/L, and APTT > 75 seconds. Factors identified
as significant covariates by univariate analysis were tested
using logistic or Cox regression multivariate analysis. All
directional p values were two-tailed, with a p value 0.05
considered significant for all tests. All analyses were per-
formed using SPSS 19.0 software (Chicago, IL, USA).
Results
Patients’ clinical characteristics
The 65 patients in this study included 42 men and 23 women
[median age at diagnosisZ 64 years (rangeZ 18e94 years)].
Peak incidence occurred at 71e80 years in both sexes, but
also at 21e30 years in women and 51e60 years in men
(Fig. 1). Themost commonbleeding symptomsweremultiple
ecchymoses, followed by soft tissue hematoma and mucosal
bleeding (Table 1). Concomitant femoral nerve neuropathy
(because of compression from retroperitoneal hematomas)
developed in four patients (6%), and bleeding occurred in 31
patients (48%), with identifiable associated disorders or
conditions (Table 2). Abnormal bleeding in 11 patients was
blamed on medications, including antibiotics, unknown
herbal drugs, and antianginal and antipsychotic drugs. The
incidence of mucosal bleeding was higher in eight patients
with active cancer (88% vs. 37% of patients without active
cancer; pZ 0.017), but the incidence of hematoma forma-
tion (13% vs. 72%, respectively; pZ 0.002) and ecchymosis
(50% vs. 86%, respectively; pZ 0.033) was lower.
Laboratory results
Forty-two patients (65%) had severe FVIII deficiency
(FVIII:C < 1%), and the remaining 23 patients (35%) hadresidual FVIII:C (median Z 3.8%; range Z 1.1e17%)
detectable. At AHA diagnosis, the median titer of FVIIIi was
19.4 BU (range Z 0.74e2414), and 31%, 11%, 29%, and 29%
of patients had low, intermediate, high, and very high FVIII
inhibitor titers, respectively. All patients had prolonged
APTT (median Z 73.7 seconds; range Z 39.2e149.2 sec-
onds), which could note be corrected by the addition of
normal plasma (data not shown). All other test results were
generally within the reference range, except for the Hb
level (median Z 9.6 g/dL; range Z 2e16 g/dL), indicating
anemia, and the LDH level (median Z 527 IU/L;
rangeZ 203e1764 IU/L; reference rangeZ 360e465 IU/L).
Arrest of acute bleeding
At the time of preparation of this manuscript, 393 episodes
of acute bleeding [median, 3 episodes per patient
(range Z 1e138)] had occurred in 54 patients (83%) at
presentation or follow-up. Among these episodes, 54 (14%)
were severe hemorrhages that occurred in 33 of these 54
patients (61%).
There was no significant difference in FVIIIi titers be-
tween patients with acute bleeding and patients with no
acute bleeding (mean  SD, 125.9  352.5 BU vs. 8.4  13.4
BU, respectively; p Z 0.276) and between patients with
severe hemorrhage and patients with mild or moderate
Table 2 Associated conditions of the 65 patients with
acquired hemophilia A.
Associated condition Patient, n (%)
Not identified 34 (52)
Identified 31 (48)
Medicationsa 11 (17)
Malignancyb 8 (12)
Autoimmune disorderc 4 (6)
Skin disorderd 3 (5)
Post-partum complication 3 (5)
Interstitial lung disease 2 (3)
a Antibiotics belong to penicillins (4 patients); herbal drugs
(5); cardiovascular medicine (1); antipsychotics (1).
b Lymphoma (3 patients); bladder cancer (2); oral cancer (1);
hepatoma (1); lung cancer (1).
c Systemic lupus erythematosus (3 patients), motor neuron
disease (1).
d Psoriasis (1 patient); photosensitive dermatitis (1); lichen
planus (1).
324 S.-Y. Huang et al.hemorrhage (mean  SD, 138.5  424.4 BU vs.
106.1  200.9 BU, respectively; p Z 0.746).
Table 3 shows the rates of response to different treat-
ments used to stop the bleeding. The rates of response to
APCC and rFVIIa were 85% and 90%, respectively, and these
agents had no marked adverse effects. Only one patient
died; the cause of death was acute ischemic stroke and
myocardial infarction 2 days after PCC infusion.
Response to FVIIIi elimination therapy
Fifty-six patients (86%) received FVIIIi elimination thera-
pies, including conventional IS (n Z 46), ITT (n Z 3), and
Rb (n Z 7) regimens. The other 9 patients did not receive
these therapies because of poor clinical conditions (nZ 6),
trivial hemorrhagic symptoms (n Z 2), and refusal of
treatment (n Z 1). The results, after a median treatmentTable 3 The percentage of acute bleeding episodes
responsive to treatment in patients with acquired hemo-
philia A.
Therapy No. of episodes a Response (%)
Bypassing agent 355
Porcine FVIII 6 83
PCC 137 80
APCC 74 85
rFVIIa 138 90
Human FVIII 38
Without plasmapheresis 5 38
With plasmapheresis 31 46
Immunoabsorption 2 0
Overall 393 81
APCC Z activated prothrombin complex concentrates;
FVIII Z factor VIII; PCC Z prothrombin complex concentrates;
rFVIIa Z recombinant activated FVII.
a Total documented episodes of acute bleeding requiring
hemorrhage control.duration of 11 weeks (rangeZ 2e164 weeks) and a follow-
up of 115 months, are summarized in Table 4. In brief, 12 of
30 patients (40%) who received prednisolone alone as their
initial therapy, had CR, and the median TCR was 12 weeks.
Among the 18 patients who did not have CR to this treat-
ment, CTA was subsequently added for 11 patients. Overall,
the results of conventional IS therapy including predniso-
lone alone initially, prednisolone subsequently combined
with CTA, and PCTA for a median treatment period of 15
weeks (range Z 2e164), indicated a CR rate of 63% and
median TCR of 16 weeks. Of the seven patients who
received the Rb regimen as their initial therapy for a me-
dian treatment period of 4 weeks (range Z 3e38), three
patients (43%) had a CR with a median TCR of 10 weeks.
Four patients died of sepsis before achieving a response.
The data for all FVIIIi elimination therapies indicate that CR
was achieved in 60% of cases with a median TCR of 16
weeks.Outcome
At the median follow-up of 115 months, 34 of the 65 pa-
tients (52%) were dead. Causes of death included FVIIIi-
related bleeding [including intracranial (n Z 5), gastroin-
testinal (nZ 3), and retroperitoneal bleeding (nZ 1), and
hemothorax (nZ 1)], sepsis (nZ 14), malignancy (nZ 5),
cardiac failure (n Z 1), chronic lung disease (n Z 1), and
others (nZ 3). The median time from diagnosis to death of
the 10 patients who died of bleeding was 2 months (95%
CI Z 0.0e8.2). The cumulative 1-, 2-, and 5-year BSM
percentages in the 65 patients were 15%, 18%, and 22%,
respectively. Among the 56 patients treated for FVIIIi, the
cumulative 1-, 2-, and 5-year BSM was significantly higher in
the patients without a CR than in patients with a CR (19%,
33%, and 49% vs. 4%, 4%, and 4%, respectively; pZ 0.0042)
(Fig. 2).
In this sample, 13 of the 56 treated patients (23%) died
of sepsis, but only 11 of these 13 patients suffered from
fatal sepsis during the treatment period (median Z 2.7
months; 95% CIZ 2.0e3.4). Therefore, 20% of the mortality
caused by sepsis may have been treatment-related (11 of
56 patients). These 11 patients had received FVIIIi elimi-
nation therapy for a median of 7 weeks (range Z 2e16).
There was a significantly higher rate of treatment-related
sepsis mortality in those treated with the Rb regimen
(n Z 4) than in those treated with IS and IT therapies
(n Z 7) (57% vs. 14%, respectively; p Z .022). Among the
four patients treated with the Rb regimen who died of fatal
sepsis, two received rituximab alone, and two (one patient
had B-cell lymphoma and another had idiopathic interstitial
lung disease) received concomitant prednisolone and
cyclophosphamide. Treatment-related neutropenia
appeared in the latter two patients. Compared to the other
three patients who survived from the Rb regimen treat-
ment, these fatal patients were older and had a lower Alb
level (median Z 69 vs. 75 years, p Z 0.682; 3.9 vs. 2.4 g/
dL, pZ 0.085, respectively). The use of the Rb regimen, as
a covariate, along with other clinical parameters, was
compared between the AHA patients who died of fatal
sepsis (n Z 11) and those who did not (n Z 45). Table 5
presents a summary of the results. These two factors (the
Table 4 Response rate and time to respond to FVIIIi elimination therapy.
Therapy Patients, n CR TCR (wk)
n (%) Median (95% CI)
Pred. alone initially 30a 12 (40) 12 (0.0e29.4)
Pred. subsequently combined CTA 11a 5 (46) 44 (5.3e82.7)
Pred. simultaneously combined CTA 14b 11 (79) 9 (2.6e15.4)
CTA alone 2c 1 (50) 19
Immunosuppression 46aþbþc 29 (63) 16 (3.1e29.0)
Immunotolerance 3 1 (33) 6
Rituximab-based 7 3 (43) 10 (8.4e11.6)
Overall 56 33 (60) 16 (9.3e22.7)
CI Z confidence interval; CR Z complete response; CTA Z cytotoxic agent; Pred Z prednisolone; Pt Z patient; TCR Z time to
complete response.
a The 11 patients were part of the 18 patient group who did not obtain CR after the induction treatment of prednisolone alone.
b The number of patients who received prednisolone and CTA simultaneously.
c The number of patients who received CTA alone.
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significantly related to fatal sepsis by univariate analysis. In
addition, other factors had a high odds ratio associated
with fatal sepsis, but were not significant on univariate
analysis. These factors included age > 65 years,
LDH > 465 IU/L, and WBC < 4.0  109/L, and all proceeded
into multivariate analysis. The use of the Rb regimen, and
PLA < 1.5  1011/L, were both verified as independent
predictors by multivariate analysis.
Two patients whose AHA was refractory to conventional
IS therapy, recovered spontaneously 13 and 23 months after
discontinuation of all treatment. Another three patients,
who received no FVIIIi treatment, also recovered sponta-
neously a median of 2 months (rangeZ 1e5) after diagnosisFigure 2 Comparison of the cumulative incidence of mor-
tality due to bleeding of patients who had CR to FVIIIi elimi-
nation therapies and those who did not (“NO” CR).of AHA. Conversely, four of the 33 patients (12%) who had a
documented CR, relapsed at a median of 5 months
(range Z 2e14) after discontinuation of all treatment.
Thereafter, one of these patients died of bleeding despite
treatment, and three others responded to the resumption
of conventional IS therapy.Predictors of survival
Univariate analysis showed that severe bleeding, no CR to
therapy, PLA < 1.5  1011/L, Alb < 3.5 g/dL, and APTT > 75
seconds, were associated with a shorter EFS. Subsequently,
multivariate Cox regression analysis identified no CR to
therapy as the only independent predictor of shorter EFS
[Hazard ratio (HR), 12.6 (95% CIZ 1.5e108.4); pZ 0.021].
Univariate analysis showed an association of age > 65
years, severe bleeding, hematoma formation, mucosal
bleeding, associated conditions, active cancer, no CR to
therapy, PLA < 1.5  1011/L, Alb < 3.5 g/dL, and
LDH > 465 IU/L with a shorter OS. However, only age > 65
years [HR Z 4.3 (95% CI Z 1.5e12.0), p Z 0.005],
PLA < 1.5  1011/L [HR Z 5.1 (95% CI Z 1.2e21.8),
p Z 0.027], and no CR to therapy [HR Z 3.6 (95%
CI Z 1.1e12.4), p Z 0.041] remained as independent
predictors of shorter OS after multivariate analysis.Discussion
To the best of our knowledge, this study of 65 AHA patients
is the largest case series of AHA in a Chinese population,
and has the best long-term follow-up at almost 10 years.
These patients have clinical characteristics similar to those
reported for other patient series,3,10,15e17 suggesting a
common underlying pathophysiology of AHA across ethnic
populations. However, no patient had rheumatoid arthritis,
which is commonly reported among patients with AHA.15
The overall treatment response and time to response
(i.e., arrest of acute bleeding and elimination of FVIIIi) in
these patients were also similar to those in the other
reports.1,4,15e17
Table 5 Comparison of clinical characteristics between acquired hemophilia A patients who had immunosuppressive therapy
related fatal sepsis and those who did not.
Item With fatal sepsis
(n Z 11)
Without fatal sepsis
(n Z 45)
Univariate analysis Multivariate analysis
n (%) Odds ratio (95% CI)
Age > 65 y 7 (63.6) 21 (46.7) 2.0 (0.5e7.8) 1.0 (0.2e6.0)
Sex, male 6 (54.5) 28 (62.2) 1.4 (0.4e5.2) d
Underlying condition 5 (45.5) 18 (40.0) 1.3 (0.3e4.7) d
FVIII:C < 1% 7 (63.6) 30 (66.7) 1.1 (0.3e4.5) d
FVIIIi titer (BU)
Low < 5 2 (18.2) 14 (31.1) ref d
5< Z intermediate Z <10 1 (9.1) 4 (8.9) 1.8 (0.1e24.7) d
10 < high Z <50 6 (54.5) 12 (26.7) 3.5 (0.6e20.7)
50 < very high 2 (18.2) 15 (33.3) 0.9 (0.1e7.6) d
Hb < 8 g/dL 5 (45.4) 15 (33.3) 1.6 (0.4e6.2) d
WBC < 4.0  109/L 2 (18.2) 1 (2.2) 9.8 (0.8e119.8) 2.1 (0.0e968.7)
PLA < 1.5  1011/L 3 (27.3) 1 (2.2) 16.5 (1.5e179.2)* 38.5 (1.3e1107.6)*
Alb < 3.5 g/dL 6 (54.5) 19 (42.2) 1.4 (0.4e5.9) d
LDH > 465 IU/L 9 (81.8) 22 (48.9) 4.7 (0.9e24.6) 8.2 (0.8e83.7)
APTT > 75 s 5 (45.5) 21 (46.7) 0.9 (0.2e3.4) d
Rituximab-based regimen 4 (36.4) 3 (6.7) 8.0 (1.5e43.7)* 8.0 (1.1e68.2)*
*Statistically significant.
Alb Z albumin; APTT Z activated partial thromboplastin time; BU Z Bethesda units; FVIIIi Z autoantibodies against the factor VIII
coagulant protein ; HbZ hemoglobin; LDHZ lactatedehydrogenase; PLAZplatelet count;WBCZwhite blood cell count; refZ reference.
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therapy was the main cause of death other than bleeding,
and accounted for 20% of the mortality. A meta-analysis
showed that the mortality rate caused by infectious com-
plications of treatment is 15%.4 Data from the acquired
hemophilia registry in the United Kingdom indicate that 33%
of AHA patients developed sepsis, and 11% of AHA patients
died of sepsis.18 A substantial proportion of AHA patients,
especially elderly AHA patients, receiving cyclophospha-
mide, died because of neutropenia-related infections, and
immunosuppressant-related side effects appeared in as
many as 53% of AHA patients treated in a single center.4 In
this study, 14% of patients treated with conventional IS and
IT therapies died of sepsis, but this rate was significantly
higher in patients receiving the Rb regimen (57%) as their
initial therapy. Although the deaths caused by sepsis during
the administration of the Rb regimen could be attributed to
patient conditions (extreme age and low Alb) and comor-
bidities (1 patient had lymphoma, and another had idio-
pathic interstitial lung disease), rituximab depletes the B
lymphocytes. Therefore, patients treated with rituximab
alone or rituximab and CTA concomitantly, could experi-
ence serious or even fatal systemic infection.19 Similarly,
two of the six (33.3%) AHA patients treated with rituximab
and concurrent prednisolone and/or cyclophosphamide in
one study died of sepsis.20 Because of the limited number of
patients in this study, the finding of higher treatment-
related fatal sepsis associated with the Rb induction
regimen, compared to other treatments, must be verified
by a prospective study with more patients enrolled. A
recent report from the European Acquired Hemophilia
Registry (EACH2) did not suggest that rituximab, as the
first-line treatment, improves outcomes or reduces side
effects in patients with AHA.21 Nonetheless, other studiesusing prednisolone and/or cyclophosphamide concurrently
with rituximab, have shown no related infectious compli-
cations.6,7 One possible explanation is that T lymphocyte
counts and serum immunoglobulin (sIg) levels remain stable
after the administration of rituximab.6 Therefore, it might
be necessary to monitor T lymphocyte counts and sIg levels
before and during the period of rituximab administration in
patients with AHA.
This is also the first study to show that a low platelet count
(< 1.5  1011/L) at AHA diagnosis is significantly and inde-
pendently associated with TRS. This mechanism is unclear,
but a low platelet count is associated with adverse outcomes
in critically ill patients, because it may aggravate the
bleeding risk.22 Moreover, a decrease in platelet count may
indicate ongoing coagulation activity on disrupted integrity
of the vessel wall, which contributes tomicrovascular failure
and organ dysfunction.22 A platelet count decline also pre-
cedes other signs of sepsis.23 Alternatively, a low platelet
count might reflect the severity of underlying diseases for
AHA, regardless of whether it is identifiable. Thus, patients
with AHA and a low platelet count at diagnosis may require
some prophylactic strategies to prevent sepsis, such as
prophylactic antibiotics and frequentmonitoring for any sign
of ongoing infection during the FVIIIi eliminating treatment.
The BSM in our patients was 15%, which is comparable to
rates in other reports (estimated rate Z 8e22%).2,4,15
Although age, response to IS therapy, associated condi-
tions, and inhibitor titers are prognostic for EFS and OS,15,17
this study shows that no CR (i.e., the absence of complete
response to therapy) was the only independent predictor of
both shorter EFS and OS. This finding is consistent with the
results of ameta-analysis.4 Therefore, although the inhibitor
can spontaneously disappear in approximately 14e35% of
patients within 12e18monthswithout FVIIIi elimination,15,24
Acquired hemophilia A in Taiwan 327it is still important to achieve a CR in AHA patients, because
of the risk of fatal bleeding, unless FVIIIi is completely
eliminated.1,4,25
The optimal first-line regimen to eradicate FVIIIi remains
controversial in AHA patients.1 A regimen might be consid-
ered superior if CR is achieved in more patients more
rapidly. This study suggests that treatment with PCTA may
be better in these respects. Likewise, interim data from the
EACH2 suggest that treatment with a combination of ste-
roids and a CTA (predominantly cyclophosphamide) achieves
CR in more patients (77%) than treatment with steroids
alone (58%) or an Rb regimen (61%). However, the median
TCR in those who responded was similar in the steroid alone
and steroid and cytotoxic groups (approximately 5 weeks)
but slower in those treated with an Rb regimen (approxi-
mately 9 weeks).21 In EACH2, the 12 patients treated with
rituximab alone had only a 42% response rate,21 which was
relatively similar to the efficacy of the Rb regimen (43%).
This study has several limitations. One is its retrospec-
tive nature. The patient number was small, and the
collection period crossed over two decades, whereas the
supportive care method, including antimicrobial agents,
changed over time. Treatments of either acute bleeding
episodes, or FVIIIi elimination therapies, were heteroge-
neous. Therefore, these findings should be confirmed by
prospective controlled studies in the future.
In summary, the clinical characteristics of the AHA pa-
tients in this study were similar to those of AHA patients
elsewhere. These data also confirm that CR to treatment is
a crucial predictor of fair EFS and OS. The choice of
treatment modality should consider TRS. Two independent
factors (the use of an Rb regimen and PLA < 1.5  1011/L at
diagnosis) were significantly associated with TRS.
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